The Biotech Analyst Group

Experienced independent investor group, since late 1990, focused on public biotech companies in Nordic markets. We let our performance speak for itself.

[The Biotech Analyst Group @BiotechAnalystG]

Disclaimer. Our content is intended for informational purpose only. Our conclusion may be wrong and may cause losses. Do your own research before making any investment.

[The Biotech Analyst Group @BiotechAnalystG]

Coegin Pharma: Phase I/II AK study on track. Danish Medical Agency approve application to start the study. Coegin Pharma follows plan, start in August 2021. https://t.co/UiHSP0Cd8K

[The Biotech Analyst Group @BiotechAnalystG]

Synact: follow up conf. 7th July on positive data from the phase 2a trial of AP1189 in Covid-19 infected patients. https://t.co/2d67MguCvi

[The Biotech Analyst Group @BiotechAnalystG]

Aegirbio: secured capacity to produce 9 million Covid diagnostic test per month, starting in August. https://t.co/jIkvLtAU0H

[The Biotech Analyst Group @BiotechAnalystG]

2cureX: https://t.co/HK1WkQnRZP

[The Biotech Analyst Group @BiotechAnalystG]

Please read our disclaimer before you invest. We may be completely wrong and any investment based on our conclusions may cause severe losses.

[The Biotech Analyst Group @BiotechAnalystG]

@xGuineapig It is actually their wording, straight from the release, so not our wording. We get your point.

[The Biotech Analyst Group @BiotechAnalystG]

SynAct Pharma: Patients treated with AP1189 recovered respiratory function on average 3.5 days quicker than did placebo treated patients, a 35% increase in recovery time.
https://t.co/FnAlKtS890

[The Biotech Analyst Group @BiotechAnalystG]

Chordate Medical:
Clinical evaluation of Chordates K.O.S treatment for rhinitis in public hospitals in Saudi Arabia now approved https://t.co/3nSM4rUJGL

[CombiGene @CombiGene]

CombiGene and Neurochase begin work to optimize the administration of CG01
https://t.co/X6Wnt0aBHm

[The Biotech Analyst Group @BiotechAnalystG]

Aegirbio: Progress according to plan. Test order worth (revenue) 100 MSEK, with potential to generate (revenue) 200 MSEK per month.

[The Biotech Analyst Group @BiotechAnalystG]

@petejmasters Don't know, not member of the fb-group. Bullish engulfing yesterday, PAS today have a conservative target of 60 SEK, should the Covid vaccine reach market the upside is even higher. In the ball park range we estimated to. However, we believe >100 SEK if vaccine is approved.

[The Biotech Analyst Group @BiotechAnalystG]

ExpreS2ion: gap closure today if you are into TA. Bullish engulfing candle in the making? Start phase II, financing sorted and phase I/II data upcoming.

[The Biotech Analyst Group @BiotechAnalystG]

Aptahem: https://t.co/OWeBwtlKyl

[The Biotech Analyst Group @BiotechAnalystG]

Scandion Oncology: positive interim results from phase II.

[Scandion Oncology @Scandion]

Scandion Oncology reports positive interim results from the CORIST Phase II study https://t.co/VwezI8qAA9

[The Biotech Analyst Group @BiotechAnalystG]

Combigene: Ready to start GMP production CG01 https://t.co/I8wvZ5dJTz

[The Biotech Analyst Group @BiotechAnalystG]

Coegin Pharma: probably a good buy opportunity today.

[The Biotech Analyst Group @BiotechAnalystG]

@Success_X1 Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021

[The Biotech Analyst Group @BiotechAnalystG]

Portfolio update: We look forward to follow our new position in Coegin Pharma. Two spinouts and start of phase I/II in August, study completed this year. In our opinion, the two spinouts are not priced in at all in current market cap (likely value when launched 100-200 MSEK).

[The Biotech Analyst Group @BiotechAnalystG]

@Success_X1 no, still waiting

[The Biotech Analyst Group @BiotechAnalystG]

Kancera: According to CEO, results from the Covid-19 study will be presented when the study is completed, hence 90 days after last patient is treated. Presentation of results after 7-days is cancelled due to lack of resources at hospitals and lab. Complete data in Q4 2021

[The Biotech Analyst Group @BiotechAnalystG]

Coegin Pharma: Technically the price is building up momentum nicely, indicating higher highs.

[The Biotech Analyst Group @BiotechAnalystG]

@Success_X1 agree, poor communication